Please login to the form below

Not currently logged in
Email:
Password:

AZ signs skin cholesterol test marketing deal with PreMD

AstraZeneca has signed a deal to market Canadian predictive medicine company PreMD's non-invasive Prevu skin cholesterol test in the US

AstraZeneca (AZ) has signed a deal to market Canadian predictive medicine company PreMD's non-invasive Prevu skin cholesterol test in the US.

The deal allows AZ to exclusively market and distribute Prevu, which the first test to use skin cholesterol to evaluate risk of advanced atherosclerosis, in the US. The agreement also gives the UK's second largest pharmaceutical company a three-month exclusive right to negotiate a global contract with PreMD.

PreMD could receive an upfront payment of USD 500,000 and is also eligible for additional milestone payments of up to USD 6m contingent on various development and revenue targets.

PreMD will also receive a 20 per cent royalty rate on AZ's net sales of the product for the first USD 30m, after which the rate will increase to 25 per cent. AZ will also fund any additional clinical trials, which PreMD would help to execute.

The product is currently being investigated by the FDA in a pivotal trial for broad clearance for patients with early heart disease.

According to PreMD, the results from the FDA should be known by Q3 2007, but added that it should not hold up the agreement with AZ.

PreMD retains exclusive rights to promote Prevu products to the life-insurance industry and other future applications of the technology under the brand.

Adele Gulfo, vice-president of healthcare innovation and corporate strategy at AZ said: "This collaboration will support the use of innovative, cost-effective technology to improve cardiovascular health by helping to identify patients at increased risk of having cardiovascular diseases such as heart attack or stroke. Identifying patients before they have an event is one of the most important challenges in American healthcare today."

AZ added that it hoped to begin marketing and distributing the product line to healthcare professionals in the US in 2008.

18th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics